A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (Results of ERSPC, Rotterdam)

被引:36
作者
Roobol, MJ
Schröder, FH
Kranse, R
机构
[1] Erasmus MC, Dept Urol, NL-3000 CA Rotterdam, Netherlands
[2] Canc Registry Rotterdam, Rotterdam, Netherlands
关键词
prostate cancer; screening; PSA; prostate biopsy; logistic regression analysis;
D O I
10.1002/pros.20352
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. The identification of predictors for prostate biopsy outcome at two screening rounds using a PSA >= 3.0 ng/ml as biopsy indication. MATERIALS AND METHODS. We compared predictors by means of descriptive statistics and logistic regression analysis in men (55-75 years) biopsied in either the 1st or 2nd screening round of ERSPC Rotterdam (interval 4 years). RESULTS. Positive predictors for biopsy outcome in both screening rounds were an increased PSA level in the absence of a previous negative biopsy (PrevNB), DRE and TRUS suspicious and a positive family history (PFH). A higher than median prostate volume was a consistent negative predictor. Having had a PrevNB at initial screening strongly reduced the chance of cancer detection at repeat screening and in addition canceled the predictive potential of PSA. CONCLUSION. If "detecting prostate cancer efficiently" were the aim, this study indicates that a "PSA only based biopsy threshold" may be replaced by another criterion incorporating, e.g., DRE, TRUS and prostate volume in men who were biopsied in the preceding 4 year interval.
引用
收藏
页码:604 / 612
页数:9
相关论文
共 12 条
[1]  
CARTER HB, 1992, CANCER RES, V52, P3323
[2]  
CARTER HB, 1993, UROL CLIN N AM, V20, P665
[3]   LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE [J].
CARTER, HB ;
PEARSON, JD ;
METTER, J ;
BRANT, LJ ;
CHAN, DW ;
ANDRES, R ;
FOZARD, JL ;
WALSH, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16) :2215-2220
[4]   Lead times and overdetection due to prostate-specific antigen screening:: Estimates from the European randomized study of screening for prostate cancer [J].
Draisma, G ;
Boer, R ;
Otto, SJ ;
van der Cruijsen, IW ;
Damhuis, RAM ;
Schröder, FH ;
de Koning, HJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) :868-878
[5]   PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml [J].
Fang, J ;
Metter, EJ ;
Landis, P ;
Carter, HB .
UROLOGY, 2002, 59 (06) :889-893
[6]   Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels 10 ng/mL [J].
Garzotto, M ;
Hudson, RG ;
Peters, L ;
Hsieh, YC ;
Barrera, E ;
Mori, M ;
Beer, TM ;
Klein, T .
CANCER, 2003, 98 (07) :1417-1422
[7]  
Griffiths K, 1996, NUTR CANC
[8]   Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years [J].
Postma, R ;
de Vries, SH ;
Roobol, MJ ;
Wildhagen, MF ;
Schröder, FH ;
van der Kwast, TH .
CANCER, 2005, 103 (04) :708-716
[9]   Parameterization of multivariate random effects models for categorical data [J].
Rabe-Hesketh, S ;
Skrondal, A .
BIOMETRICS, 2001, 57 (04) :1256-1263
[10]   Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands) [J].
Roobol, MJ ;
Kirkels, WJ ;
Schröder, FH .
BJU INTERNATIONAL, 2003, 92 :48-54